Phase 2
Stories
-
MAXONA announces first patient dosed in Phase 2 trial of MAX-001 for acute pain
MAXONA Pharmaceuticals reported that the first participant was dosed in its Phase 2 clinical trial of MAX-001 for acute pain following surgical extraction of impacted third molars (NCT07937657). The study plans to enroll 276 patients and evaluate safety and efficacy across a dose range.